Drug Trial Radar · NCT00926562
A Safety Comparison of Iopromide and Iodixanol in Renal Impaired Patients
Last checked: Nov 19, 2026Latest source record: Jun 27, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
592
Actual
Start
Feb 2009
Primary completion
Dec 2010
Study completion May 2011
Sponsor
- Lead sponsor
- Chinese PLA General HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 23, 2009
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The investigators intend to find out which contrast agent has less kidney toxicity in renal impaired patients undergoing cardiac angiography or percutaneous coronary intervention (PCI).
Conditions
- Kidney Failure, Chronic
Interventions
Iopromide (Ultravist)Drug
Iopromide (contrast agent), 370 mgl/ml, an nonionic, monomeric, LOCM
Iodixanol (Visipaque)Drug
Iodixanol (contrast agent) 320 mgl/ml, a nonionic, dimeric, IOCM
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients exhibiting a relative increase in serum creatinine >= 50% from baseline.Time frame: day 3 postreatment
Locations
19 sites in 1 country. Site status is shown where the registry gives one.
Beijing CHAO-YANG Hospital
Beijing, Beijing Municipality, China
General Hospital of Armed Police Forces
Beijing, Beijing Municipality, China
Peking University Third Hospital
Beijing, Beijing Municipality, China
Beijing Shi Jing Shan Hospital
Beijing, Beijing Municipality, China
Beijing Hospital
Beijing, Beijing Municipality, China
Chinese PLA general hospital
Beijing, Beijing Municipality, China
Henan Provincial People's Hospital
Zhengzhou, Henan, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Wuhan Asia Heart Hospital
Wuhan, Hubei, China
The Second Hospital of Xiangya
Changsha, Hunan, China
China-Japan Union Hospital of Jilin University
Changchun, Jilin, China
The First Hospital of Jilin University
Changchun, Jinlin, China
Shanghai First People's Hospital
Shanghai, Shanghai Municipality, China
Renji Hospital affiliated to Shanghai Jiao Tong University
Shanghai, Shanghai Municipality, China
Changhai Hospital affiliated to the second millitary medical university
Shanghai, Shanghai Municipality, China
Tianjin Chest Hospital
Tianjin, Tianjin Municipality, China
Teda International Cardiovascular Hospital
Tianjin, Tianjin Municipality, China
The Second Hospital Affiliated to Zhejiang University
Hangzhou, Zhejiang, China
Sir Run Run Shaw Hospital affiliated to Zhejiang
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.